These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 13679362)

  • 1. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport.
    Dawson M; Wirtz D; Hanes J
    J Biol Chem; 2003 Dec; 278(50):50393-401. PubMed ID: 13679362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis sputum: a barrier to the transport of nanospheres.
    Sanders NN; De Smedt SC; Van Rompaey E; Simoens P; De Baets F; Demeester J
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1905-11. PubMed ID: 11069833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
    Broughton-Head VJ; Smith JR; Shur J; Shute JK
    Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
    Nafee N; Forier K; Braeckmans K; Schneider M
    Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
    Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
    Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.
    Broughton-Head VJ; Shur J; Carroll MP; Smith JR; Shute JK
    Am J Physiol Lung Cell Mol Physiol; 2007 Nov; 293(5):L1240-9. PubMed ID: 17827252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
    Dasgupta B; Brown NE; King M
    Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
    Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
    Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the transport of lipoplexes through cystic fibrosis sputum.
    Sanders NN; Van Rompaey E; De Smedt SC; Demeester J
    Pharm Res; 2002 Apr; 19(4):451-6. PubMed ID: 12033379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.
    Stigliani M; Manniello MD; Zegarra-Moran O; Galietta L; Minicucci L; Casciaro R; Garofalo E; Incarnato L; Aquino RP; Del Gaudio P; Russo P
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):337-45. PubMed ID: 26741302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent Yield Stress of Sputum as a Relevant Biomarker in Cystic Fibrosis.
    Ghanem R; Roquefort P; Ramel S; Laurent V; Haute T; Le Gall T; Aubry T; Montier T
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
    Sun F; Tai S; Lim T; Baumann U; King M
    Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.
    Hida K; Lai SK; Suk JS; Won SY; Boyle MP; Hanes J
    PLoS One; 2011; 6(5):e19919. PubMed ID: 21637751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrier properties of gastrointestinal mucus to nanoparticle transport.
    Crater JS; Carrier RL
    Macromol Biosci; 2010 Dec; 10(12):1473-83. PubMed ID: 20857389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
    Feng W; Garrett H; Speert DP; King M
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B; King M
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic Fibrosis Sputum Rheology Correlates With Both Acute and Longitudinal Changes in Lung Function.
    Ma JT; Tang C; Kang L; Voynow JA; Rubin BK
    Chest; 2018 Aug; 154(2):370-377. PubMed ID: 29559310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
    Griese M; App EM; Duroux A; Burkert A; Schams A
    Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microstructural alterations of sputum in cystic fibrosis lung disease.
    Duncan GA; Jung J; Joseph A; Thaxton AL; West NE; Boyle MP; Hanes J; Suk JS
    JCI Insight; 2016 Nov; 1(18):e88198. PubMed ID: 27812540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.